pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$KYTXKyverna Therapeutics, Inc.

$KYTX
Emeryville, CA, USupdated 14d ago
Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
mivocabtagene autoleucel
Myasthenia Gravis

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase3KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravisrecruitingn=66
  • —A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101recruitingn=70
  • phase2KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndromeactive not recruitingn=25
  • phase2KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritisactive not recruitingn=2
  • phase2KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritisactive not recruitingn=6
  • phase2KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosisactive not recruitingn=3
  • phase2KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosisactive not recruitingn=120

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Mar 13, 26grantGRASSO MARC · Chief Financial Officer10,000 sh
  • Mar 13, 26grantGRASSO MARC · Chief Financial Officer65,000 sh
  • Mar 13, 26grantBiddle Warner Weston · Chief Executive Officer58,000 sh
  • Mar 13, 26grantBiddle Warner Weston · Chief Executive Officer350,000 sh
  • Mar 13, 26grantGEHCHAN NAJI · See Remarks18,000 sh
  • Mar 13, 26grantGEHCHAN NAJI · See Remarks105,000 sh
🐶 Hiring Signal
No open roles indexed yet — view Kyverna Therapeutics, Inc. jobs →

News

  • Chutes & Ladders—Cue lines up new CMO and research head
    Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.
    fiercebiotech · 28d ago
identifiers
ticker
$KYTX
SEC CIK
0001994702
country
US
source
sec_tickers
top tags
Immunology1
mentioned in
1news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 14m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?